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ABSTRACT 
 
 Significant progress has been made in understanding the molecular basis of pediatric 
malignancies. Mechanisms of pediatric acute leukemia induction include hyperdiploidy, 
aberrant expression of proto-oncogenes, and activation of transcription factors or kinases by 
aberrant fusion genes. Molecular analysis of these alterations has facilitated the recognition 
of distinct groups with different sensitivity to therapy, and identified potential targets for 
antileukemic agents. Similar analysis of pediatric soft tissue and bone tumors also resulted 
in the identification of specific fusion genes, and their characterization has contributed 
greatly to understand their biology. Molecular assays for these rearrangements have become 
important tools in classifying these tumors, providing important prognostic data. However, 
the understanding of mechanisms involved in the pathogenesis of many other pediatric 
malignancies, including some embryonal tumors -believed to arise due to perturbation of the 
normal developmental program- is still vastly incomplete. 
 The Department of Pathology at Texas Children’s Hospital is one of the Children’s 
Oncology Group (COG) reference centers for pediatric liver tumors. We have been 
particularly interested in the biology of hepatoblastoma, the most common type of pediatric 
liver tumor. Although a number of cytogenetic and molecular abnormalities have been 
described for this type of embryonal tumor, its pathogenesis is still poorly understood. In an 
attempt to explore the role of different signaling pathways in this disease, we analyzed the 
expression patterns of different histologic subtypes of hepatoblastoma using cDNA 
microarray analysis, QRT-PCR and immunohistochemistry. Wnt signaling pathway, critical 
both in development and in neoplasia, appears to be particularly relevant in these tumors. 
Mutations of the β-catenin gene are present in over 90% of hepatoblastomas, leading to 
activating transcription of a number of target genes. The pattern of β-catenin expression and 
type of mutation in groups of tumors are crucial to understand the corresponding differences 
in their gene expression profiles.  Our findings are consistent with a relationship between 
poor histologic phenotype and β-catenin activation, indicating the potential utility of targeted 
gene expression assays to identify molecular events related to the pathogenesis and 
prognosis of hepatoblastomas. 
Integration of clinical, morphologic, phenotypic, cytogenetic and molecular data has 
become the basis of novel prognostic prediction and therapeutic strategies in pediatric  
leukemia. Similarly, integration of new genetic and molecular data with clinical, and other 
diagnostic information will be crucial for accurate classification of pediatric tumors, risk 
stratification and successful development of new therapies for pediatric oncologic patients.  
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INTRODUCTION 
Significant progress has been achieved during the past few decades in understanding 
the molecular basis of numerous pediatric malignancies. In some instances this has resulted 
in the development of genetic and molecular tests that are being progressively integrated in 
the diagnosis and clinical management of these patients.  
The pediatric and adult cancer disease spectrum is different, as it is the stem cell 
population targeted by mutations, the type and number of necessary mutations to induce a 
fully malignant phenotype, and the internal homeostatic environment of the host (developing 
versus a fully mature). All these results in a different approach to diagnose pediatric cancer, 
as many of these processes lack morphologic evidence of differentiation and are difficult to 
classify. Most of pediatric cancer patients are enrolled in cooperative group therapy protocols 
(90% of children in USA) which are tailored to specific tumor types and subgroups, often 
requiring assessment of biologic tumor markers. {Gilliland, 2002 #1}  
 
PEDIATRIC HEMATOPOIETIC MALIGNANCIES 
The best example of how the application of newly gained biological knowledge in a type 
of malignancy has resulted in improvements in diagnosis, classification and clinical 
management, is pediatric hematopoietic malignancies. True treatment success has been 
achieved in many pediatric acute leukemias and lymphomas, much more so than for adult 
hematopoietic malignancies. These differences in therapeutic success are probably due to a 
combination of factors, including biological differences of the neoplastic processes, host-
dependent features and treatment strategies, and also a better understanding of normal 
hematopoietic development and of the molecular pathology of these malignancies.( Pui, 
Acute Lymphoblastic Leukemia, NEJM 2004) {Pui, 2004 #2} 
 
 
 
PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 
Pediatric ALL is the most common malignancy in childhood, representing approximately 
50 percent of all pediatric cancers. During the last decade a better understanding of normal 
hematopoietic development and of the molecular events involved in leukemic malignant 
transformation, has been achieved. As a result, significant improvements have occurred in 
our ability to diagnose, sub classify and treat these patients. During the last decade the 
survival rates have increased to close to 80 percent overall, as prognostic markers have been 
identified and risk adapted therapeutic protocols have been implemented. To the 
conventional methods of ALL diagnosis (morphology, cytochemistry, immunophenotyping) a 
number of genetic and molecular diagnostic techniques have progressively become part of the 
diagnostic work-up and monitoring of ALL  patients, including one or several of the 
following: conventional cytogenetics, southern blotting, polymerase Chain Reaction (PCR), 
Fluorescence in situ Hybridization (FISH), Spectral Karyotyping (SKY), and Comparative 
Genomic Hybridization (CGH). {Margolin, 2006 #3} 
A small subset of important genetic abnormalities of variable frequency (Table 1) have 
been identified in pediatric Acute Lymphoblastic Leukemia (ALL), and are presently being 
used in several clinical protocols for therapeutic stratification of  these patients. The 
presence or absence of a number of chromosomal rearrangements and the resulting fusion 
genes are used as markers which, in combination with a number of other clinical parameters 
(immunophenotype, DNA index, age, white cell count, central nervous system or testicular 
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involvement, and early response to therapy) serve to assess these patients standard, high or 
very high clinical risk, and to assign them to therapeutic protocols accordingly. (Pui et al, 
The New England Journal of Medicine, 339, 9, 605-615, 2002?) {Pui, 2001 #4} 
Molecular testing in pediatric ALL fusion transcripts derived from chromosomal 
translocations has become critical for risk-stratification of patients and optimizing treatment 
strategies. Patient-specific transcripts can also be used as markers to monitor relapse or 
minimal residual disease.  
Pediatric acute lymphoblastic leukemia has become the best example of integration of 
genetic and molecular biological markers in routine diagnosis, risk assessment and 
monitoring of pediatric cancer patients. (Downing 2002,  Pui 2001, {Pui, 2001 #4} 
Weitzman 2002) 
In the last few years cDNA microarray technology has been extensively utilized to 
identify distinct leukemia subtypes that can be defined exclusively on their expression 
profiles (Ross, M. E. et al. Blood 2003;102:2951-2959) {Ross, 2003 #5}. This newly gained 
knowledge has resulted in a number of challenges for the molecular testing of pediatric ALL 
patients, the first one being the potential need for individual molecular characterization of 
newly diagnosed leukemia patients. This will require the implementation of multiplexed 
diagnostic assays, sufficiently sensitive, efficient and cost effective requiring flexible new 
platforms to allow easy inclusion of new markers and potential of expansion into proteomics 
and pharmacogenomics testing. 
Our Department at Texas Children’s Hospital is in the process of implementing a new 
ALL translocations Bead-based Assay (Ambion/Luminex). This technology, a combination of 
multiplex RT-PCR (Reverse Transcription, Polymerase Chain Reaction) and detection of 
spectrally addressable fluorescent beads, allows the analysis of multiple targets in a single-
well (ninety-six well format). This high throughput multiplexed assay is being implemented 
for the amplification and detection of six common leukemia associated fusion transcripts in a 
single well, with a very short turn-around time (5 h for 96 assays) in a sensitive (reliably 
detects 1 fusion-transcript carrying leukemia cell in 100-1000 cells) and cost-effective 
manner. (Wallace et al, Leukemia 2003) {Wallace, 2003 #6} 
 
LYMPHOMAS OF CHILDREN AND ADOLESCENTS 
Malignant lymphomas represent the third most common pediatric cancer (between 8 
and 10 percent of all pediatric malignancies). The four most common pathological subtypes 
are Burkitt lymphoma (40%), lymphoblastic lymphoma (30%), diffuse large B-cell lymphoma 
(20%), and Anaplastic Large Cell Lymphoma (ALCL, 10%).  
Cairo, Pediatr. Blood Cancer Vol.45, 6 Pages: 753-769, 2005. {Cairo, 2005 #7} 
Some of the most relevant recent developments in the molecular biology of two subtypes 
of pediatric NHLs: anaplastic large cell lymphoma (ALCL) and Burkitt lymphoma, 
particularly those most relevant to the diagnosis of these lymphoma subtypes, will be 
discussed briefly. 
 
Anaplastic Large Cell Lymphoma (ALCL)  
Anaplastic Large Cell Lymphoma, previously designated as “Ki-1 lymphoma” for its 
characteristic CD30 immunoreactivity, is a T-cell non-Hodgkin lymphoma, representing 
between 10 and 15 percent of the total pediatric NHLs (Cairo rf). This lymphoma subtype 
was initially associated with the presence of a t(2;5) translocation, which was cloned by  
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Morris et al. (1994) describing the genes involved in the resulting fusion gene: the 
NPM (nucleophosmin) gene, located on chromosome 5q35, and the ALK (anaplastic 
lymphoma kinase) gene, located on chromosome 2p23. Aberrant expression of ALK protein, a 
novel receptor tyrosine kinase of the insulin receptor family, is linked to tumorigenesis in 
ALK-positive ALCL, as well as in some other tumors (49, 50, 51 from Cairo). {Morris, 1994 
#8} {Bischof, 1997 #9} {Kutok, 2002 #10}A number of other variant translocations involving 
at least six other ALK partner genes have been recently described (Table 2). 
Histologic identification of the typical ALCL anaplastic morphology or any its many 
morphological variants, in combination with phenotyping and its characteristic CD30 
immunoreactivity, are used to initially identify these lesions. Although a number of RT-PCR 
and Fluorescence in situ hybridization assays (ALK specific FISH) are available to document 
translocations associated with ALCL, immunohistochemical detection of aberrant ALK 
protein expression is most commonly used. {Simonitsch, 1996 #11} {Beylot-Barry, 1996 #12} 
{Armstrong, 2005 #13} 
 
Burkitt Lymphoma 
Histologic identification of the Burkitt lymphoma or L3 ALL blasts morphology, 
immunophenotyping, and correlation with the presence of CMYC oncogene (8q24.12-q24.13) 
rearrangements is usually required for accurate classification of these malignancies. 
Documenting this rearrangements can be either done by conventional cytogenetics, 
identifying the presence of the t(8;14) or variant translocations (t(2;8), t(8;22)),  or C-MYC 
(8q24.13) oncogene rearrangements by FISH. More recently, the application of CISH 
(Chromogenic In Situ Hybridization) probes to document CMYC oncogene rearrangements 
on tissue sections, touch imprints and other cellular specimens, has allowed the 
simultaneous identification of the genetic rearrangement within their histologic context. 
{Heerema, 2005 #14} 
 
PEDIATRIC SOLID TUMORS 
The majority of pediatric solid tumors, differently to adult malignancies, more commonly 
of epithelial origin, are either sarcomas or tumors of neuroectodermal origin. Many of these 
lesions are difficult to accurately classify by morphological means, as they are frequently 
poorly differentiated or undifferentiated neoplasms. Multiple diagnostic approaches are often 
required and ancillary tests are necessary to confirm the initial diagnostic and clinical 
impression in these patients.  
Genetic abnormalities found in pediatric solid tumors include a number of chromosomal 
translocations (and other chromosomal rearrangements as deletion, inversions and 
insertions) loss of tumor suppressor genes, amplification of oncogenes, abnormal 
methylation, genomic imprinting, defective DNA repair mechanisms and telomerase activity. 
However, from the molecular diagnostic point of view, only those recurrent, well-
characterized genetic changes, rigorously correlated with specific tumor types and subtypes 
should be considered for clinical use.  
No specific genetic rearrangements have been identified in a proportion of pediatric and 
adult sarcomas (Table 5: Sarcomas with complex Karyotypes). However, systematic 
cytogenetic analysis of pediatric solid tumors identified a number of tumor-specific 
chromosomal translocations. Molecular cloning of these rearrangements resulted in the 
characterization of their breakpoints and the identification of fusion genes, chimeric 
transcripts and proteins that result of these translocations. As a result of this, we have a 
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better understanding of the molecular mechanisms involved in normal development in some 
cases, and malignant transformation of these tumors. Is also provided molecular pathologists 
with genetic markers for tumor classification and is impacted therapy which is becoming 
more risk-based and tumor specific. A number of translocation-specific novel therapeutic 
strategies are also being evaluated for these patients. {Borden, 2003 #15}  
In addition of conventional cytogenetics and other karyotyping techniques (such as CGH 
and SKY) a number of molecular techniques, including RT-PCR, FISH and more recently 
CISH are clinically applied for the identification of tumor specific chromosomal 
translocations, fusion genes and fusion transcripts. The advantage of conventional 
cytogenetic analysis is the large amount of information provided by a complete karyotype, 
however it requires alive, dividing cells, its resolution is low, is expensive and slow. Both RT-
PCR and FISH/CISH are affordable and fast tests, but non-informative if negative. RT-PCR 
allows an unlimited number of primer to be design, but requires RNA obtained from the 
tissue tested. On the other hand, FISH/CISH probes are limited and test results may be 
difficult to interpret. Other conventional and ancillary techniques used for diagnosing 
pediatric solid tumors are included in Table 4. Probably the most important element to 
remember when a number of tests are incorporated for diagnosing these types of 
malignancies is that molecular testing should always be used in the context of other 
diagnostic tests and not used alone to arrive to a diagnosis. {Triche, 2006 #16} 
The following section will mostly focus in tumor-defining chromosomal translocations 
identified in two pediatric sarcomas: synovial sarcoma and alveolar rhabdomyosarcoma. The 
most recent advances in the application of molecular diagnostic testing to these two sarcoma 
types, carrying characteristic, well characterized chromosomal rearrangement with well-
established diagnostic, therapeutic and prognostic relevance, will be discussed.  
 
Synovial sarcoma 
Synovial sarcoma is an aggressive, relatively common sarcoma (approximately 10% of all 
soft tissue sarcomas) of unknown histogenesis that affects children and young adults, with a 
slight male predominance. {Fletcher, 2000 #18} The most common sites involved are the 
limbs, and particularly areas adjacent to joints, although they can arise in almost any area of 
the body (trunk, mediastinum, abdominal wall, head and neck, lung and pleura) {Shmookler, 
1982 #20; Shmookler, 1982 #19} {Fetsch, 1993 #21} {Zeren, 1995 #22}Histologically there are 
two subtypes of synovial sarcoma: monophasic, composed of a spindle cells component, or 
biphasic, containing areas with variable degrees of epithelial differentiation, form carcinoma-
like to “occult” subtle cases. 
Cytogenetically both monophasic ans biphasic synovial sarcomas share a recurrent 
reciprocal t(X;18)(p11.2;q11.2) translocation. This translocation fuses the SYT gene from 
chromosome 18q11 to either of three homologous genes at Xp11, SSX1, SSX2 and rarely 
SSX4 (only two cases have been described). {Crew, 1995 #23} {de Leeuw, 1995 #24} The SSX1 
and SSX2 genes encode closely related proteins (81% identity). The N-terminal portion of 
each SSX protein exhibits homology to the Kruppel-associated box (KRAB), a transcriptional 
repressor. Both the SYT-SSX1 and the SYT-SSX2 hybrid transcripts encode fusion proteins 
in which the C-terminal 8 amino acids of the normal SYT protein have been replaced by 78 
amino acids encoded by an SSX gene. {Thaete, 1999 #25} SYT and SSX proteins appear to be 
transcriptional regulators primarily through protein-protein interactions (Ladanyi 
Oncogene Sep 10; 20 (40):5755-62, 2001), {Ladanyi, 2001 #26} SYT acting as an activator 
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of transcription and SSX as a repressor.(dos Santos,  Genes Chromosomes and Cancer 
2001 Jan:31(1):1-14.) {dos Santos, 2001 #27} 
Cytogenetic studies on series of synovial sarcomas demonstrated a near-diploid 
karyotype in a majority of the cases with the t(X;18)(p11.2;q11.2) translocation as the sole 
cytogenetic abnormality present in approximately a third of synovial sarcomas. (Sandberg 
2002) {Sandberg, 2002 #28} Other chromosomal changes include numerical changes and no 
other recurrent structural abnormalities.  
Molecular detection of SYT-SSX1 and 2 fusions has been demonstrated to be of 
tremendous clinical value. PCR analysis demonstrated the presence of SYT-SSX1 or SYT-
SSX2 fusion transcripts in approximately 95% synovial sarcomas examined, indicating that 
the detection of these hybrid transcripts by PCR may represent a useful diagnostic method. 
Sequence analysis demonstrated further heterogeneity in the fusion transcripts with the 
formation of 2 distinct SYT-SSX1 fusion junctions and 2 distinct SYT-SSX2 fusion junctions. 
Coexisting SYT-SSX1 and SYT-SSX2 has been reported in 10% SYT-SSX positive primary 
tumors {Yang, 2002 #29}.  
Kawai and colleagues {Kawai, 1998 #30} found a relationship between the type of 
fusion transcript and the histologic subtype (SYT-SSX1associated mostly with biphasic, and 
SYT-SSX2 with monophasic types) as well as with the prognosis, with a significantly better 
metastasis-free survival associated with the SYT-SSX2 subtype. Skytting {Skytting, 1999 
#31} suggested that the base pair differences between the SSX transcripts may have biologic 
significance. The impact of the SYT-SSX Fusion Type on the Clinical Behavior of Synovial 
Sarcoma has since become a subject of scientific debate. Ladanyi {Ladanyi, 2002 #32} and 
colleagues found fusion type “the single most significant prognostic factor by multivariate 
analysis in patients with localized disease at diagnosis” for synovial sarcoma. However, a 
recently published European multicenter, retrospective analysis study found that is 
histologic grade, but not SYT-SSX fusion type, the most important prognostic factor 
determining these patients prognosis. {Guillou, 2004 #33} Further studies, with careful 
clinical, morphologic and molecular correlation will be necessary to determine the 
significance of the molecular fusion type in synovial sarcoma.  
Alveolar rhabdomyosarcoma 
Rhabdomyosarcoma (RMS), the most common soft tissue sarcoma in children, is a small 
round cell tumor of skeletal muscle histogenesis, thought to arise as a consequence of loss of 
growth control and differentiation of myogenic cells {Wexler, 2006 #34}. Their differential 
diagnosis often depends of the identification of rhabdomyoblasts or the detection of muscle-
specific proteins in the tumor cells.{Dias, 2000 #35} {Qualman, 1998 #36} {Parham, 2001 
#37}Histologically three main types of RMS can be identified : botryoid, embryonal, and 
alveolar, associated with poorer prognosis. Separate categories have been established for 
undifferentiated sarcoma, anaplastic and sarcoma NOS (not otherwise specified) subtypes. 
Cytogenetic analysis revealed chromosomal abnormalities, primary aneuploidies, in all 
subtypes of RMS. In the alveolar subtype two specific chromosomal translocations have been 
identified. The t(2;13)(q35;q14) translocation can be cytogenetically detected in 
approximately 60% of alveolar RMS {Whang-Peng, 1986 #38} {Whang-Peng, 1992 #39}. This 
translocation juxtaposes the Pax3 gene on 2q35, a transcription factor functional during 
early neuromuscular development, to FKHR gene (also known as FoxO1A) on 13q14. FKHR 
is a member of the forkhead family of transcription factors.  {Barr, 1993 #41} {Shapiro, 1993 
#42} {Galili, 1993 #43} As a result of this translocation the 5’ portion of the Pax3 gene, 
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including an intact DNA binding domain, is fused to FKHR, resulting in a chimeric 
transcript and protein containing the Pax3 DNA-binding domain and the distal half of the 
fork head and C-terminal region of FKHR. A less common variant of the translocation, fusing 
Pax7 gene (another member of the forkhead family of transcription factors located on 1p36) 
to FKHR, and resulting in a t(1;13)(p36;q14) translocation, has also been associated with 
alveolar RMS {Biegel, 1991 #44}. A third t(2;2)(q35;p23) translocation fusing Pax3 to NCOA1 
(nuclear receptor co activator) gene {Wachtel, 2004 #45}has been recently identified by gene 
expression profiling. 
Gene expression profiling has demonstrated the activation of a myogenic transcription 
program by the Pax3/FKHR fusion oncogene (Khan 1999) and it is assumed that these 
unique fusion genes activate the transcription of downstream genes, ultimately responsible 
for the transformed phenotype seen in these tumors, however, the exact mechanism is still 
under investigation {Sublett, 1995 #46} {Bennicelli, 1996 #47} 
Molecular identification of these fusion transcripts, mostly using RT-PCR assays and 
FISH are helpful in diagnosing these tumors, particularly when limited diagnostic material 
available or when microscopic and immunohistochemical findings are equivocal. {Barr, 1995 
#48} {Biegel, 1995 #49} {McManus, 1996 #50}{Anderson, 1997 #51} {Edwards, 1997 #52} 
{Athale, 2001 #53}In a recent Children’s Oncology Group (COG) study, Pax3-FKHR and 
PAX7-FKHR fusion transcripts were identified in a majority of alveolar RMSs analyzed (77 
percent), with the first being almost twice as common as the Pax7 fusion in these tumors. 
{Sorensen, 2002 #54} Pax7 fusion genes are more often associated with lesions in the 
extremities occurring in younger patients and have a better outcome than those carrying a 
Pax3 fusion, representing another example of sarcomas with fusion gene variants of 
apparent clinical relevance. Barr and colleagues have documented a true “fusion-negative” 
subset of alveolar RMS represented by a genetically diverse subsets of tumors, including low-
expressors of the common fusion genes, fusion variants with other genes and true negative 
case.{Barr, 2002 #55} 
Expression of myogenin in rhabdomyosarcoma has been associated with the alveolar 
subtype and worse prognosis. {Dias, 2000 #56}{Hostein, 2004 #57} 
 
OTHER PEDIATRIC SOLID TUMORS 
Pediatric Liver Tumors: hepatoblastoma 
Neoplasms of epithelial origin represent only a minority of pediatric malignant solid 
tumors. Malignant tumors of the liver account approximately 1.1 percent of malignant 
childhood tumors in the United States with hepatoblastoma being the most common, 
particularly in early childhood.{Mueller, 2006 #58} 
Hepatoblastoma is an embryonal liver tumor, with an incidence that is still rising, of 0.5 
to 1.5 cases per million children per year.{Mueller, 2006 #58} The reason(s) for the rising 
incidence are unclear, but may be due to combined effects of increasing survival rates of 
extreme prematurity, as well as exposures to environmental toxins in utero or early in life. 
{Buckley, 1989 #59} It affects children between six months and three years of age, with 
nearly 90% of hepatoblastomas seen in the first five years of life, with a distinct male 
predominance with a male to female ratio of 2:1. 
 Hepatoblastoma represents the most common type of primary pediatric liver 
malignancy, and accounting for just over 1% of all pediatric cancers.  These tumors originate 
from immature liver precursor cells (hepatoblasts), and may recapitulate some aspects of the 
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liver development. Histologically, all hepatoblastomas are composed of epithelial tissue, and 
about one third of them show also focal mesenchymal differentiation. The epithelial 
component can be further subdivided into 4 types: pure fetal (31%), embryonal (19%), 
macrotrabecular (3%) and small undifferentiated (3%), with most of the tumors showing a 
combination of more than one of these types.   
Accepted staging systems include the conventional POG/CCG systems based on post-
surgical status, and the International/SIOP system of pre-surgical staging. {Mueller, 2006 
#58} The primary treatment of hepatoblastoma is surgical resection; however, chemotherapy 
plays an important role by increasing the number of tumors that are resectable. Both staging 
and histology play important roles in determining the prognosis in these patients.  Virtually 
100% of patients with Stage I (completely resected at diagnosis), favorable histology (i.e. pure 
fetal type), survive, while the survival rates of patients with Stage IV tumors (distant 
metastases at diagnosis) of all histologies is 0-27%.  Patients with low stage tumors that 
demonstrate unfavorable histology (i.e. small cell), usually recur, and have poor over-all 
prognosis. {Haas, 2001 #60} With chemotherapy, there is an 85% survival rate for Stage III 
hepatoblastomas having diverse histology. {Mueller, 2006 #58}  The characterization of gene 
expression profiles of tumor cells from the treatment failure cases versus the responsive 
tumors, as well as those of the tumor cells that remain viable after effective chemotherapy, is 
an ultimate goal of the longer term project. 
Some hepatoblastomas have been associated with constitutional genetic abnormalities, 
congenital malformations, and familial cancer syndromes, such as Beckwith-Wiedeman 
syndrome (BWS), familial polyposis coli (FAP), and rare cases of Prader-Willi and Li-
Fraumeni syndrome, but most cases are sporadic.{Mueller, 2006 #58} {Oda, 1996 #61} 
Multiple cytogenetic and molecular cytogenetic abnormalities, have been described especially 
in sporadic hepatoblastoma. These include: extra copies of chromosomes 2q and 20, frequent 
chromosome breaks at 1q12-q21 and 2q35-37, and chromosomal CGH based descriptions of 
gains of material on chromosomes 1, 2, 7, 8, 17, 20, and 22q as well as loss of 4q 
materials.{Mueller, 2006 #58} {Ma, 2000 #62} {Weber, 2000 #63} The clinical significance of 
such observations are unclear. They are, therefore not incorporated into any of the staging or 
grading systems. One of the long-term goals of this project is to correlate these molecular 
cytogenetic changes both with gene expression changes, and overall clinical behavior. 
Activation of the canonical Wnt signaling pathway is a consistent finding in 
hepatoblastoma. The Wnt pathway has long been known to direct growth and pattering 
during embryonic development, as well as being one of the key signaling pathways 
regulating cell growth, motility and differentiation. {Behrens, 2004 #64} {Lind, 2004 #65} 
This pathway has also emerged as a critical regulator of stem cells {Rattis, 2004 #66} 
integrally involved in tightly regulated self-renewal of stem and progenitor cells, as well as 
cancer development in the digestive (intestinal) epidermal and hematopoietic systems. 
{Taketo, 2004 #67} Nuclear β-catenin is the hallmark of Wnt signaling activation. β-catenin 
is an important scaffolding protein involved in both cellular adhesion and as the central 
regulator of canonical Wnt target gene transcription  {Reya, 2005 #68}. In quiescent cells, β-
catenin is bound to the cellular membrane by E-cadherin and also to α-catenin, thus linking 
cellular adhesion to the cytoskeleton. Cytoplasmic β-catenin is maintained at a low level by a 
degradation complex including APC, Axin and Axin-2. This complex presents β-catenin to the 
CK1 and GSK3 kinases, resulting in phosphorylation of β-catenin at key serine and 
threonine residues in exon-3. This results in the recruitment of β-TrCP-containing E3 
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ubiquitin ligase to these phosphorylated residues and proteosomal degradation of 
cytoplasmic β-catenin. The ubiquitin ligase EBI also targets β-catenin for degradation in a 
p53-induced manner {Liu, 2001 #69}, thus linking DNA damage to inhibition of β-catenin 
mediated transcription. Upon binding of WNT ligand to the Frizzled/LRP co-receptor 
complex, the Dishevelled protein inhibits GSK3, allowing cytoplasmic accumulation and 
subsequent nuclear translocation of β-catenin. In the nucleus, β-catenin binds to BCL9 
through the first four Arm repeats. β-catenin and BCL9 juxtapose Pygopus and the TCF/LEF 
transcription factors. The recently discovered BCL9-2 also links β-catenin to TCF/LEF 
{Brembeck, 2004 #70}. The nuclear TCF(LEF)/β-catenin/BCL9(BCL9-2)/Pygopus complex 
facilitates the transcription of numerous canonical WNT target genes, including those 
regulating diverse cellular activities such as proliferation (CCND1), apoptosis (cMyc, 
survivan), migration (MMP-7, MMP-26), growth factor ligands and receptors (FGF18, MET), 
WNT transcription factors (TCF-1, LEF1) and inhibitors of WNT canonical signaling (Axin2, 
DKK1, BTRC) {Nusse, 2006 #71} 
 Mutations in the genes that constitute the canonical WNT signaling pathway are 
frequently seen in adult cancers, including colorectal, liver, endometrial, prostate, thyroid, 
skin and brain tumors. {Brembeck, 2004 #70} Recent evidence also implicates this pathway 
in the development of childhood tumors (liver, kidney, brain and pancreas) (Koesters 2003) 
that typically arise from germinal tissues, as opposed to the epithelial origin of the majority 
of  adult cancer, most likely from a rapidly dividing stem cell. Nuclear translocation of β-
catenin is present in 60-90% of hepatoblastomas {Takayasu, 2001 #72}{Park, 2001 #73} and 
has been associated with prognosis. Different types of CTNNB1 gene activating mutations, 
including point mutations in exon-3 and deletions either confined to exon-3 or extending from 
exon-3 to exon-4, have also been documented in hepatoblastomas with a frequency that 
varies from 15 to over 70% of cases, depending of the design of the primers used. Mutations 
of other components of the canonical WNT pathway in hepatoblastoma include rare 
inactivating mutations in APC, Axin and Axin2 {Oda, 1995 #74} {Taniguchi, 2002 #75} {Koch, 
2004 #77}. Although mutations in these members of the canonical Wnt pathway appear to be 
frequent in hepatoblastoma, a large correlation study including b-catenin status (mutation 
type), histological subtype and expression pattern of other components of this pathway and, 
most important, of its target genes, has not been previously reported. 
 Important information about the pathogenesis of childhood cancer has derived from the 
study of normal embryonic development. The similarities between growth and differentiation 
of cells and tissues and the dysregulation of these events in oncogenesis are evident at 
multiple levels. At the molecular level, this relationship has become substantial with the 
discovery that many proto-oncogenes encode components of signal transduction pathways 
that direct normal development, including the Wnt signaling pathway. {Koesters, 2003 #78} 
The hepatoblastoma progenitor undifferentiated cell of origin (hepatoblast) which equivalent 
during embryonic development (liver stem cell) is programmed to undergo massive 
proliferation, appears to be somehow locked in this uncontrolled proliferative state in these 
tumors. 
Our Department of Pathology at Texas Children’s’ Hospital and Baylor College of 
Medicine in Houston, Texas, is one of the two institutions designated for histological review 
of pediatric liver tumors by the Children’s Oncology Group in the United States. We have 
developed an increasing interest in studying the biology of hepatoblastoma and particularly 
in identifying biological differences that may explain behavior of histological subtypes and 
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could be used as clinical markers. 
We have studied 41 hepatoblastoma specimens and performed genomic profiling using 
BAC array CGH, gene expression profiling using Affymetrix chips and QRT-PCR 
(Qualitative Reverse Transcription, Polymerase Chain Reaction) and are validating some of 
our data using immunohistochemistry, and in-situ hybridization. We are particularly 
interested in the Wnt signaling pathway and the important role of its abnormal over 
activation may play in hepatoblastoma pathogenesis. One of our main objectives is to 
investigate additional mechanisms by which defects in regulation of the Wnt signaling 
pathway contribute to tumor progression in different subtypes of hepatoblastoma.  
In order to investigate Wnt activation and hepatoblastoma we performed analysis of 
CTNNB1 gene mutation status and β-catenin expression pattern in different subtypes and 
explored the possible contribution of additional canonical Wnt pathway molecules (epigenetic 
mechanisms) in Wnt signaling activation. We also analyzed the status of Wnt/Tcf target 
genes in hepatoblastoma.  
We found markedly increased nuclear expression of β-catenin (particularly in the 
higher-grade tumor components) in hepatoblastomas with embryonal/small cell histology, 
and point mutations, deletions within or confined to the entire exon three, (rarely no 
CTNNB1 mutations). By contrast, hepatoblastomas with pure fetal epithelial histology 
showed a predominantely membranous and only rare nuclear β-catenin expression, as well 
as predominantly large deletions including the entire exon three and most of exon four of 
CTNNB1 gene. Our hypothesis is that when mutations are confined to exon-3 the BCL9-
interaction domain is maintained, as well as the transcription of WNT target genes, resulting 
in a more aggressive phenotype. Large deletions including the BCL9-interacting domain 
would not be as capable of facilitating canonical WNT target gene expression (as wild type 
CTNNB1). 
We studied other canonical and non canonical Wnt pathway molecules by Real-time 
quantitative reverse transcription-polymerase chain reaction (QRT-PCR), using SYBR Green 
chemistry (value of the target gene calculated in relation to a control sample using ΔΔCt 
method). This analysis demonstrated: down regulation of canonical Wnt pathway genes , 
induction of upstream antagonists of canonical Wnt signaling, and induction of some non-
canonical Wnt pathway genes in the majority of Hepatoblastomas 
We are now in the process of studying Wnt/Tcf target genes in hepatoblastoma 
(36 downstream targets, a subset of 14 involved in feed-back regulation) by QRT-PCR, 
microarray analysis and tissue immunohistochemistry in order to investigate the possibility 
of a hepatoblastoma subtype-specific TCf target program that may explain clinical behavior 
and response to therapy. 
We expect that a better understanding of hepatoblastoma biology, based on a systematic 
analysis of biologically important signaling pathways, and integration of this information 
with histology and other tumor markers, will lead to new biologically relevant and 
therapeutically significant tumor classification 
 
CONCLUSIONS 
The diagnosis of cancer and particularly, the diagnosis and prognostication of pediatric 
malignancies is undergoing tremendous challenges and improvements as pathologist and 
cancer diagnosis is becoming part of the new molecular era. Classification of pediatric 
malignancies based on molecular markers and gene expression signatures has already 
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began. Pathologists will be playing a crucial translating role in assay development, clinical 
validation and diagnostic integration of new biological markers. This integration of new 
diagnostic information is already become clinically necessary to correctly diagnose, classify, 
and clinically stratify pediatric cancer patients. The integration of additional and more 
complex diagnostic parameters will become gradually more important in order to make 
optimal therapeutic decisions. 
 
 
Abbreviations:  
 
ALL, Acute Lymphoblastic Leukemia 
PCR: Polymerase Chain Reaction 
RT-PCR: Reverse Transcription, Polymerase Chain Reaction 
FISH: Fluorescence in situ Hybridization 
SKY: Spectral Karyotyping 
CGH: Comparative Genomic Hybridization. 
CISH: Chromogenic In Situ Hybridization 
NHL: non-Hodgkin lymphoma 
RMS: Rhabdomyosarcoma 
QRT-PCR: Qualitative Reverse Transcription, Polymerase Chain Reaction 
BAC: Bacterial Artificial Chromosomes 
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TABLES 
Table 1.: Genetic abnormalities and risk assessment in pediatric ALL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Anaplastic Lymphoma Kinase (ALK, 2p23) translocations in ALCL 
 
Abnormality   Fusion gene        
t(2;5)(p23;q35)  ALK/NPM  
t(2;22)(p23;q11.2)  ALK/CLCTL  
t(2;22)(p23;q11.2)  ALK/MYH9  
t(1;2)(q35;p23)  ALK/TPM3  
t(2;3)(p23;q21)  ALK/TFG  
t(2;17)(p23;q25)  ALK/ALO17  
inv(2)(q23q35)  ALK/ATIC  
 
 
Table 3: Most common translocations and gene fusions in sarcomas 
 
Tumor     Translocation                           Fusion gene 
 
Alveolar rhabdomyosarcoma   t(2;13)(q35;q14)              PAX3-FKHR  
       t(1;13)(p36;q14) PAX7-FKHR  
Alveolar soft-part sarcoma   t(X;17)(p11.2;q25) ASPL-TFE3  
Clear-cell sarcoma    t(12;22)(q13;q12) ATF1-EWS  
Congenital fibrosarcoma and 
 mesoblastic nephroma    t(12;15)(p13;q25) ETV6NTRK3  
DFSP and giant-cell fibroblastoma  t(17;22)(q22;q13)           COL1A1PDGFB 
Desmoplastic round-cell tumor                t(11;22)(p13;q12)  WT1-EWS  
Ewing and peripheral AND pPNET  t(11;22)(q24;q12) EWS-FLI1  
       t(21;22)(q22;q12) EWS-ERG  
       t(7;22)(p22;q12) EWS-ETV1  
       t(17;22)(q12;q12) EWS-E1AF  
       t(2;22)(q33;q12)   FEV-EWS  
Inflammatory myofibroblastic tumor               t(2;19)(p23;p13.1)          ALK-TPM4  
       t(1;2)(q22-23;p23) TPM3-ALK  
Myxoid chondrosarcoma, extraskeletal                 t(9;22)(q22;q12)              EWSCHN(TEC) 
       t(9;17)(q22;q11)         RBP56CHN(TEC)  
       t(9;15)(q22;q21)             TCF12  
Myxoid liposarcoma    t(12;16)(q13;p11)         TLS(FUS)CHOP  
       t(12;22)(q13;q12) EWS-CHOP  
Synovial sarcoma                  t(X;18)(p11;q11)            SYT/SSX1/2/4   
 Cytogenetics Fusion Frequency Prognosis 
t(9;22)(q34;q11.2) BCR/ABL  3-4% Unfavorable 
t(4;11)(q21;q23) AF4/MLL  2-3% Unfavorable 
t(1;19)(q23;p13.3) PBX/E2A 6% Unfavorable 
 t(12;21)(p13;q22) TEL/AML1 16-29% Favorable 
Hyperdiploid >50  N/A 20-25 Favorable 
Hypodiploid N/A 5% Unfavorable 
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Table 4: Diagnostic Methods for Pediatric Tumor Diagnosis 
 
(Adapted from: Triche T, Hicks JM and  and Sorensen PHB: “Diagnostic 
Pathology of Pediatric Malignancies” In Pizzo and Poplack: Pediatric Oncology, 
Chapter 8) 
 
Method Application 
Light Microscopy Mandatory in all cases 
Immunohistochemi   stry First-choice ancillary, widely used 
RT-PCR Most common Mol dx, now routine 
FISH (CISH) Supplanting CG in many cases 
ISH  Specialized use (EBV) 
Special stains Still useful in some cases 
Electron Microscopy Still widely used 
Cytogenetics Needed if no FISH probes available 
Molecular CG: SKY, CGH SKY useful in dx, CGH in LOH 
Sequencing Rarely useful (p53 mutations) 
 
Table 5: Sarcomas with complex Karyotypes  
 
Osteosarcoma 
Rhabdomyosarcoma 
 Embryonal 
 Pleomorphic 
Leiomyosarcoma  
Fibrosarcoma  
High-grade undifferentiated pleomorphic sarcoma  
Chondrosarcoma 
Liposarcoma 
  Well differentiated/dedifferentiated  
  Pleomorphic liposarcoma 
Malignant Peripheral Nerve Sheath Tumor 
Angiosarcoma 
 
